Ikena Oncology Inc. (IKNA)
1.11
-0.09 (-7.50%)
At close: Apr 04, 2025, 3:59 PM
1.11
0.00%
After-hours: Apr 04, 2025, 03:59 PM EDT
Company Description
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs.
Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway.
It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer.
The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Ikena Oncology Inc.

Country | United States |
IPO Date | Mar 26, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 10 |
CEO | Dr. Mark Manfredi Ph.D. |
Contact Details
Address: 645 Summer Street Boston, Massachusetts United States | |
Website | https://ikenaoncology.com |
Stock Details
Ticker Symbol | IKNA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001835579 |
CUSIP Number | 45175G108 |
ISIN Number | US45175G1085 |
Employer ID | 00-0000000 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Mark Manfredi Ph.D. | President, Chief Executive Officer & Director |
Dr. Jotin Marango M.D., Ph.D. | Chief Operating Officer, Chief Financial Officer, Head of Corporate Development & Treasurer |
Bob Lally | Senior Vice President of Finance & Operations |
David Damphousse M.S. | Senior Vice President of Clinical Development Operations |
Jeffrey Ecsedy Ph.D. | Chief Development Officer |
Rebecca Cohen | Vice President of Investor Relations, Corporate Strategy & Communication |
Valdas Jurkauskas Ph.D. | Senior Vice President of Technical Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 18, 2025 | S-4 | Filing |
Mar 06, 2025 | ARS | Filing |
Mar 06, 2025 | 10-K | Annual Report |
Feb 14, 2025 | SCHEDULE 13G | Filing |
Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Feb 13, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Jan 10, 2025 | 425 | Filing |
Dec 31, 2024 | SCHEDULE 13G | Filing |
Dec 23, 2024 | 425 | Filing |